Clinical trial

Effects of RDX-002 on Postprandial Triglycerides in Patients Discontinuing GLP-1 Agonists

NCT06640972

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2024-09-27

PhasePHASE2

Study timeline

Study start (actual)2024-09-27Date precision: day

Registry last updated2026-07-02

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Triglyceridesunresolved

Weight Gain Trajectoryunresolved

Cholesterol, Elevatedunresolved

Interventions

RDX-002DRUG

PlaceboDRUG

Sponsors & collaborators

Response Pharmaceuticalslead sponsor

Mapped research locations

Saint PaulMinnesota, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06640972 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.